Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
A Young Adult Man with Cognitive Changes, Gait Difficulty, and Renal Insufficiency
Neurol 100:206-212, Stamm,B.,et al, 2023
Clinicopathologic Conference, Functional Vitamin B12 Deficiency from Use of Nitrous Oxide
NEJM 388:1893-1900, Case 15-2023, 2023
Clinicopathologic Conference, Pernicious Anemia (Vitamin B12 Deficiency)
NEJM 380:665-674, Case 5-2019, 2019
Progressive Weakness and Memory Impairment in a Middle-aged Man
JAMA 320:197-198, DeFilippis, E.M.,et al, 2018
A Man with Tingling Fingers
BMJ 346:f1443, Larkman, M.,et al, 2013
Clinicalpathologic Conference, Vitamin B12 Deficiency due to Pernicious Anemia
NEJM 366:1626-1633, Case 13-2012, 2012
Symptoms of B12 Deficiency Can Occur in Women of Child Bearing Age Supplemented with Folate
Neurol 58:1572-1573, Drazkowski,J.,et al, 2002
Increased Plasma Methylmalonic Acid Level Does Not Predict Clinical Manifestations of Vitamin B12 Deficiency
Arch Int Med 161:1534-1541, Hvas,A.,et al, 2001
Neuropsychiatric Disorders Caused by Cobalamin Deficiency in the Absence of Anemia or Macrocytosis
NEJM 318:1720-1728, 1752-17541988., Lindenbaum,J.,et al, 1988
Clinicopathologic Conference, Vitamin B12 Deficiency Due to Pernicious Anemia
NEJM 390:747-756, Case 6-2024, 2024
A 13-Year-Old Boy with Subacute-Onset Spastic Gait
JAMA Neurol 78:e1-e2, Xie, N.,et al, 2021
Analysis of 70 patients with hydrocephalus due to cobalamin C deficiency
Neurol 95:e3129-e3137, He, R.,et al, 2020
Subacute Progressive Sensorimotor Symptoms
BMJ 365:doi:10.1136/bmj.l1923, Francis, A.,et al, 2019
Risk Factors of Hyperammonemia in Patients with Epilepsy Under Valproic Acid Therapy
Medicine 93:e66, Tseng, Y.L.,et al, 2014
Clinicopathologic Conference, Adult T-cell Leukemia-lymphoma Associated with HTLV-1
NEJM 367:552-563, Case 24-2012, 2012
A Young Man with Progressive Subcortical Lesions and Optic Nerve Atrophy
Neurol 79:e63, Komatsuzaki, S.,et al, 2012
MRI in Methylmalonic Acidemia
Neurol 74:e14, Bindu, P.S.,et al, 2010
Chitosan May Decrease Serum Valproate and Increase Risk of Seizure Reappearance
BMJ 339:a2163, Striano,P.,et al, 2009
Efficacy of Folic Acid Supplementation in Stroke Prevention: A Meta-Analysis
Lancet 369:1876-1882,1841, Wang,X.,et al, 2007
Glycogen-Storage Disease Type II
eMedicine, May 2, Ibrahim,J. &McGovern,M., 2006
Homocysteine and Stroke: Evidence on a Causal Link From Mendelian Randomisation
Lancet 365:224-232, 194, Casas, J.P., et al, 2005
Seizures Following Reduction in Phenytoin Level After Orally Administered Folic Acid
Neurol 64:1982, Steinweg,D.L.&Bentley,M.L., 2005
Hyperhomocysteinemia as an Independent Risk Factor for Silent Brain Infarction
Neurol 61:1595-1599, Kim,N.K.,et al, 2003
Valproate-Induced Hyperammonemic Encephalopathy in the Presence of Topiramate
Neurol 54:230-232, Hamer,H.M.,et al, 2000
Valproate, Hyperandrogenism, and Polycystic Ovaries
Arch Neurol 57:1064-1068, Isojarvi,J.I.T. & Tapanainen,J.S., 2000
Clumsiness, Confusion, Coma, and Valproate
Lancet 353:1408, Ellaway,C.J.,et al, 1999
Management Issues for Women with Epilepsy,A Review of the Literature
Neurol 51:949-956, Zahn,C.A.,et al, 1998
Analysis of Prenatal and Gestational Care Given to Women with Epilepsy
Neurol 51:1039-1045, Seale,C.G.,et al, 1998
Practice Parameter,Management Issues for Women with Epilepsy (Summary Statement)
Neurol 51:944-948, Rpt of the Quality Stnds Subcmte AAN, 1998
Antiepileptic Drugs
NEJM 334:168-175, Brodie,M.J.&Dichter,M.A., 1996
Obesity and Endocrine Disorders in Women Taking Valproate for Epilepsy
Ann Neurol 39:579-584, 5591996., Isojarvi,J.I.T.,et al, 1996
Association Between Plasma Homocysteine Concentrations and Extracranial Carotid-Artery Stenosis
NEJM 332:286-291, 3281995., Selhub,J.,et al, 1995
Valproic Acid-Induced Hyperammonemic Encephalopathy:MR Appearance
AJNR 15:1779-1781, Baganz,M.D.&Dross,P.E., 1994
Polycystic Ovaries and Hyperandrogenism in Women Taking Valproate for Epilepsy
NEJM 329:1383-1388, Isojarvi,J.I.T.,et al, 1993
Comparison of Sprinkle Versus Syrup Formulations of Valproate for Bioavailability, Tolerance, and Preference
J Pediatr 120:634-638, Cloyd,J.C.,et al, 1992
Ticlopidine
Editorial, Lancet 337:459-4601991., , 1991
Diagnosis and Management of Neural-Tube Defects Today
NEJM 324:690-691, Hobbins,J.C., 1991
Effect of Food on the Serum Concentration Profile of Enteric-Coated Valproic Acid
Neurol 38:1319-1322, Fischer,J.H.,et al, 1988
Breakthrough Seizure Following Substitution of Depakene Capsules with a Generic Product
Neurol 37:1885, MacDonald,J.T., 1987
Bilateral Lucency of the Globus Pallidus Complicating Methylmalonic Acidemia
Ann Neurol 20:364-366, Korf,B.,et al, 1986
Safe Readministration of Valproate after an Episode of Hepatotoxicity
Ann Neurol 13:688, Ramsay,R.E., 1983
Plasma Concentrations of Sodium Valproate:Their Clinical Value
Ann Neurol 14:38-42, Turnbull,D.M.,et al, 1983
Sodium Valproate-induced Hyperammonemia Without Clinical Hepatic Dysfunction
Neurol 32:206-208, Zaret,B.S.,et al, 1982
Phenytoin-valproate Interaction:Importance of Saliva Monitoring in Epilepsy
BMJ 284:13-16, Knott,C.,et al, 1982
Monitoring of Serum Amylase Levels During Valproic Acid Therapy
Ann Neurol 11:217-218, Bale,J.F.,et al, 1982
Asymptomatic Hyperammonemia in Patients Receiving Valproic Acid
Arch Neurol 39:591-592, Murphy,J.V.,et al, 1982
Valproic Acid & Secondary Hyperammonemia
Neurol 31:1173-1174, Rawat,S.,et al, 1981
Valproic Acid
NEJM 302:661-666, Brown,T.R., 1980